Abbott and Novo Nordisk have entered into a partnership to provide integrated digital solutions to people with diabetes, using insulin.
The collaboration will enable insulin data to be shared between Novo Nordisk connected insulin pens and digital health tools compatible with Abbott’s FreeStyle Libre portfolio of products.
The FreeStyle Libre system reads glucose levels through a sensor that can be worn on the back of the upper arm eliminating the need for routine finger pricks, enabling users to capture and view their real-time glucose levels, their eight-hour glucose history, and how their glucose is currently changing on their smartphone.
Integrating these two products will enable healthcare professionals, caregivers and people with diabetes to view glucose and insulin data together to help them make more informed treatment decisions and to have a more meaningful and productive conversation about health outcomes.
“It is our aim at Abbott to continuously provide life-changing technology to people living with diabetes,” said Jared Watkin, senior vice president of Diabetes Care, Abbott.
“Diabetes is a time-intensive condition to manage. People with diabetes must make a variety of decisions every single day about their glucose monitoring, nutrition, insulin and medication intake.
“By enabling insulin dosing data from Novo Nordisk′s connected pens to be shared with our digital health tools, we′ll be able to help further eliminate those daily hassles for people, so they have more time to live a fuller, healthier life.”
